^
Association details:
| Biomarker: | IDH2 mutation |
|---|---|
| Cancer: | Glioma |
| Drug: | Synribo (omacetaxine mepesuccinate) (Apoptosis stimulant, MCL1 inhibitor, MYC inhibitor, Protein synthesis inhibitor, G1-S-specific cyclin-D1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Generation, characterization, and drug sensitivities of 12 patient-derived IDH1-mutant glioma cell cultures
Published date:
08/02/2021
Excerpt:
A set of twelve patient-derived IDHmt cell cultures was established....we selected one compound from each subclass for further validation: gemcitabine, teniposide, daunorubicin, romidepsin, dactinomycin, regorafenib, and omacetaxine. We replaced the proteasome inhibitor bortezomib with marizomib....For the taxanes we opted to include paclitaxel...This validation set revealed high overall sensitivity to each of the compounds...Our drug screening studies reveal lack of sensitivity to IDHmt inhibitors, but sensitivity to a set of nine available anti-cancer agents.
DOI:
10.1093/noajnl/vdab103
